Novartis, based in Basel, Switzerland, ranks #5 with a brand value of USD $13.496 billion.
The company develops therapies across several areas: cardiovascular and metabolic, eye care, immunology and dermatology, neuroscience, and oncology. Novartis strengthened its oncology portfolio during the past 12 months in a deal with GSK (GlaxoSmithKline), through which Novartis acquired GSK’s oncology products and research and development (R&D) and, in turn, sold GSK the bulk of its global vaccines business.
The Novartis corporate brand has an above average bearing on healthcare professional (HCP) decision-making; Novartis aims to provide solutions that address the evolving needs of patients worldwide. For HCPs, Novartis leads the industry with its proactive and innovative approaches to comprehensive health solutions. The survey respondents attribute significant value to the company’s comprehensive approach beyond clinical therapies, incorporating information technology and non-traditional innovations and partnerships, including collaborations with companies like Google, which appear be driving choice for Novartis.